Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

1
Player Avatar gdesignr (< 20) Submitted: 3/20/2008 9:22:37 AM : Outperform Start Price: $6.15 HALO Score: +29.78

This stock seems to truly have a halo around it and should perform nicely as a mover and a shaker. Jump on now to cash in.

Featured Broker Partners


Advertisement